NECLIFE11.90

Nectar Lifesciences Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹231 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,685.61,673.10.05.0
Other Income13.01.99.312.3
Total Income1,698.71,675.09.317.3
Expenses
+ Cost of Materials Consumed1,242.41,250.70.03.4
+ Purchases of Stock-in-Trade0.00.00.00.0
+ Changes in Inventories-40.2117.30.0-0.1
+ Employee Benefit Expense84.796.51.93.7
+ Finance Costs87.174.636.136.3
+ Depreciation & Amortisation60.762.40.30.5
+ Other Expenses245.6235.058.887.1
Total Expenses1,680.41,836.597.2130.9
EBITDA153.1-26.5-60.7-89.2
EBIT92.4-88.8-61.0-89.7
Profit
PBT before Exceptional Items18.3-161.5-87.9-113.6
+ Exceptional Items0.00.00.088.2
Pretax Income18.3-161.5-87.9-25.5
+ Deferred Tax13.3-47.9-30.5-39.8
Tax Expense13.3-47.9-30.5-39.8
Net Income5.0-113.7-292.9-245.1
+ Net Income — Continuing Ops5.0-113.7-57.314.4
+ Net Income — Discontinued Ops0.00.0-235.5-259.4
+ Other Comprehensive Income-0.30.50.10.1
Total Comprehensive Income4.7-113.1-292.8-245.0
Per Share
Basic EPS0.22-5.07-13.40-11.37
Diluted EPS0.22-5.07-13.40-11.37
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.00.0-374.3-439.3
+ Tax — Discontinued Operations0.00.0-138.7-179.9
Other Comprehensive Income — detail
+ Other Comprehensive Income0.50.1
+ Items NOT to be Reclassified to P&L-0.50.50.1
+ Tax on Items NOT to be Reclassified0.00.0
+ Tax on Items NOT to be Reclassified — alt tag-0.2
+ Items to be Reclassified to P&L0.00.0
+ Tax on Items to be Reclassified0.0
+ Tax on Items to be Reclassified — alt tag0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.22-5.07-2.620.35
Diluted EPS — Continuing Operations0.22-5.07-2.620.35
Basic EPS — Discontinued Operations0.000.00-10.78-11.72
Diluted EPS — Discontinued Operations0.000.00-10.78-11.72
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit483.4305.10.01.6
Gross Margin %28.6818.2332.79
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)18.3-161.5-87.9-113.6
− Exceptional Items (reconciliation)0.00.00.088.2
Net Income Adj (tax-effected)5.0-113.7-292.9-280.3
EPS Adj0.22-5.07-13.40-13.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital22.422.419.419.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.